Pasireotide injection (Signifor)

Covered for adults ≥18 with Cushing’s disease when pituitary surgery is not an option or was not curative (FDA) and compendially for adults with endogenous Cushing’s syndrome awaiting surgery or awaiting radiotherapy response; pediatric use is excluded. Authorization requires prescription by or consultation with an endocrinologist/specialist plus documentation of diagnosis and surgical candidacy/awaiting status, initial approval 4 months (reauthorization 12 months for responders in Cushing’s disease), and dosing 0.3–0.9 mg SC twice daily with hepatic (Child‑Pugh B) start at 0.3 mg BID titratable to 0.6 mg BID.

"Treatment of adult individuals (18 years of age or older) with Cushing's disease for whom pituitary surgery is not an option or has not been curative (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.